Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Having IP, But No Compounds, Sention Signs Deal With Merck

Jan. 21, 2005

By Jennifer Boggs

Having IP, But No Compounds, Sention Signs Deal With Merck

Jan. 21, 2005

By Jennifer Boggs

Synta Files For $115M IPO; Proceeds To Push Pipeline

Jan. 20, 2005

By Jennifer Boggs

Synta Files For $115M IPO; Proceeds To Push Pipeline

Jan. 20, 2005

By Jennifer Boggs

Compound Therapeutics Gets $15.5M In Expanded Financing

Jan. 19, 2005

By Jennifer Boggs

Compound Therapeutics Gets $15.5M In Expanded Financing

Jan. 19, 2005

By Jennifer Boggs

Scion's New CEO: Push Product Development, Look For Partners

Jan. 18, 2005

By Jennifer Boggs

Scion's New CEO: Push Product Development, Look For Partners

Jan. 18, 2005

By Jennifer Boggs

Oxxon In-Licenses Xenova Platform, Cancer Product

Jan. 14, 2005

By Jennifer Boggs

Oxxon In-Licenses Xenova Platform, Cancer Product

Jan. 14, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...